DBV Technologies
publicly owned French biopharmaceutical firm headquartered in Bagneux, France
DBVT Nasdaq
ISIN FR0010417345 SEC CIK 1613780 LEI 969500PVBQFWQKVDMD80
Follow DBV Technologies
Weekly email: filings, results
Revenue, last quarter
$1.6M
−42.9% vs same quarter last year
Net income
−$64.5M
−94.3% vs same quarter last year
EPS, diluted
−$0.14
+41.7% vs same quarter last year
Operating cash flow
−$51.5M
−59% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$147.2M |
| FY24 | $0 | −$114.1M |
| FY23 | $0 | −$72.7M |
| FY22 | $0 | −$96M |
| FY21 | $0 | −$98.1M |
| FY20 | $0 | −$159.7M |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | −$78.3M |
| FY22 | −$52.2M |
| FY21 | −$105M |
| FY20 | −$163.7M |